RESUMEN
BACKGROUND: Recent studies about inter-reporter differences and patient-reported outcomes (PROs) in childhood cancer from Western countries showed that caregiver proxy reports tend to overestimate symptom burdens in comparison with children's self-reports. However, the results from Western countries may not be generalizable to Asian countries. METHODS: This paper is a secondary analysis of a validation study of the Japanese pediatric version of the Memorial Symptom Assessment Scale including 88 dyads of children aged 7-12 years and 74 dyads of children aged 13-18 years and their caregivers. The study assessed the inter-reporter differences of eight and 31 symptom burdens calculated as symptom scores in children aged 7-12 years and 13-18 years, respectively, and the association between inter-reporter differences and the characteristics of children and caregivers. RESULTS: The majority of children and caregivers scored equally at the dyadic level for almost all symptoms. However, 37.5% of symptoms in children aged 7-12 years and 10.0% of symptoms in children aged 13-18 years showed significant inter-reporter differences, suggesting a general tendency of caregivers to underestimate their children's symptom burden. The caregiver's age was the characteristic most frequently associated with magnitude of inter-reporter differences. CONCLUSIONS: Caregiver proxy reports may be a reliable source of PROs in Japanese children with cancer, as self-reported and caregiver proxy-reported symptom burdens were generally concordant. However, as some significant inter-reporter differences were observed, an effort should be made within the medical community to evaluate the parent-child relationship to minimize inter-reporter differences and achieve better symptom management.
Asunto(s)
Neoplasias , Carga Sintomática , Humanos , Niño , Japón , Cuidados Paliativos , Autoinforme , CuidadoresRESUMEN
Rhinocerebral mucormycosis (RCM) can lead to internal carotid artery thrombosis. Here, we report the first case of RCM with temporal artery thrombosis following HLA-haploidentical stem cell transplantation in an adolescent presenting with low-grade fever, right mandibular pain, and right jaw claudication. This case suggests that RCM can cause temporal artery thrombosis and should be considered as a differential diagnosis in severely immunocompromised patients with maxillary sinusitis presenting with jaw claudication.
Asunto(s)
Mucormicosis/complicaciones , Trasplante de Células Madre/efectos adversos , Arterias Temporales/patología , Trombosis/etiología , Adolescente , Encefalopatías/complicaciones , Encefalopatías/diagnóstico , Diagnóstico Diferencial , Humanos , Huésped Inmunocomprometido , Enfermedades Maxilomandibulares/patología , Sinusitis Maxilar , Mucormicosis/diagnóstico , Dolor , Trasplante Haploidéntico/efectos adversosRESUMEN
OBJECTIVE: Langerhans cell histiocytosis (LCH) is characterized by immature dendritic cell proliferation, infiltration of LCH lesions by various inflammatory cells, and a lesional cytokine storm. It is classified into three groups on the basis of disease extent, namely, multisystem with risk-organ involvement (MS+), multisystem without risk-organ involvement (MS-), and single-system (SS) disease. We comprehensively analyzed whether serum levels of cytokines/chemokines reflect the disease extent. METHODS: Serum samples from 52 children with LCH (eight, 25, and 19 with MS+, MS-, and SS, respectively) and 34 control children were analyzed quantitatively for 48 humoral factors. DNA samples extracted from biopsied LCH lesions from 12 patients were tested for BRAF V600E status. RESULTS: The LCH patients had significantly higher serum levels of IL-1Ra, IL-3, IL-6, IL-8, IL-9, IL-10, IL12, IL-13, IL-15, IL-17, IL-18, TNF-α, G-CSF, M-CSF, MIF, HGF, VEGF, CCL2, CCL3, CCL7, CXCL1, and CXCL9 than the controls by univariate analysis. Of these IL-9, IL-15 and MIF were significant by multivariate analysis; but not differed between MS and SS diseases. MS disease associated with significantly higher IL-2R, IL-3, IL-8, IL-18, M-CSF, HGF, CCL2, CXCL1, and CXCL9 levels than SS disease by univariate analysis. Of these, CCL2 and M-CSF were significant by multivariate analysis. IL-18 levels were significantly higher in MS+ disease than MS- disease. The LCH patients with BRAF V600E mutation had higher serum levels of CCL7. CONCLUSION: Numerous inflammatory cytokines and chemokines play a role in LCH. Of those, more specific ones reflect the disease extent (MS vs. SS and MS+ vs. MS-) or the BRAF V600E mutation status. It is thought that the most responsible cytokines and chemokines involved in the poor outcome may become future candidate therapeutic targets in LCH.
Asunto(s)
Quimiocinas/sangre , Citocinas/sangre , Histiocitosis de Células de Langerhans/inmunología , Adolescente , Quimiocinas/inmunología , Niño , Preescolar , Citocinas/inmunología , Femenino , Histiocitosis de Células de Langerhans/sangre , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Histiocitosis de Células de Langerhans/genética , Humanos , Lactante , Proteína Antagonista del Receptor de Interleucina 1/sangre , Interleucina-10/sangre , Interleucina-15/sangre , Interleucina-17/sangre , Interleucina-18 , Interleucina-6/sangre , Masculino , Mutación , Proteínas Proto-Oncogénicas B-raf/genética , Factor de Necrosis Tumoral alfa/sangreRESUMEN
Pediatric anaplastic large cell lymphoma (ALCL) is a chemosensitive malignancy, but about 30% of patients experience relapse. In most of these patients, a second complete remission is obtainable with salvage chemotherapy, though relapse free survival rates are as low as 30-60%. Herein, we report a 6-year-old boy with relapsed anaplastic lymphoma kinase (ALK) positive ALCL successfully treated with vinblastine monotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reduced intensity conditioning (RIC) regimen, from his father. One HLA locus from the father was mismatched. The boy had neither severe graft-versus-host disease nor transplantation related complications. He is currently well and has remained disease free for 10 months, to date, since transplantation. Allo-HSCT with a RIC regimen may be a promising treatment strategy for relapsed ALK positive ALCL based on obtaining graft-versus lymphoma effects as well as reducing transplantation-related mortality.
Asunto(s)
Trasplante de Médula Ósea , Linfoma Anaplásico de Células Grandes/terapia , Niño , Humanos , Masculino , Inducción de Remisión , Acondicionamiento Pretrasplante , Trasplante Homólogo , Resultado del TratamientoRESUMEN
Medulloepithelioma of the central nervous system (CNS) is a rare primitive neuroectodermal tumor characterized by highly malignant behavior occurring in early childhood. Few cases have been reported and optimal management remains unknown. Here, we report a case of CNS medulloepithelioma successfully treated with high-dose chemotherapy (HDCTX) followed by autologous stem cell transplantation (auto-SCT) without radiotherapy. At the last follow-up, 3.0 years after onset, the patient was alive with no sign of relapse and normal development. To the best of our knowledge, this is the first reported case of long-term survival of CNS medulloepithelioma treated by HDCTX/auto-PBSCT without radiotherapy.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Tumores Neuroectodérmicos Primitivos/terapia , Trasplante de Células Madre de Sangre Periférica , Busulfano/administración & dosificación , Preescolar , Terapia Combinada , Relación Dosis-Respuesta a Droga , Humanos , Quimioterapia de Inducción , Masculino , Melfalán/administración & dosificación , Tumores Neuroectodérmicos Primitivos/patología , Pronóstico , Inducción de Remisión , Trasplante AutólogoRESUMEN
A patient with acute lymphoblastic leukemia who was hypersensitive to native Escherichia coli L-asparaginase (L-asp) underwent readministration of the L-asp without serious adverse effects for 11 doses using a desensitization protocol every time. Monitoring of anti-L-asp antibody and L-asp activity levels revealed that the serum L-asp activity was below the effective levels during the administration of first 6 to 7 doses because of extremely high levels of anti-L-asp IgG. Sustained L-asp activity was attained since the eighth dose was administered, when the antibody levels were <5 U/mL. L-asp activity levels in patients with L-asp hypersensitivity should be monitored during the desensitization courses to ensure a sufficient L-asp activity.
Asunto(s)
Antineoplásicos/inmunología , Asparaginasa/inmunología , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Asparagina/metabolismo , Preescolar , Hipersensibilidad a las Drogas/sangre , Ensayo de Inmunoadsorción Enzimática , Escherichia coli/inmunología , Humanos , MasculinoAsunto(s)
Antineoplásicos/efectos adversos , Cladribina/efectos adversos , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Síndromes Mielodisplásicos/inducido químicamente , Antineoplásicos/uso terapéutico , Cladribina/uso terapéutico , Femenino , Histiocitosis de Células de Langerhans/complicaciones , Humanos , Lactante , Síndromes Mielodisplásicos/complicacionesAsunto(s)
Disgerminoma/diagnóstico , Neoplasias Ováricas/diagnóstico , Fosfopiruvato Hidratasa/sangre , Adolescente , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/sangre , Antígeno Ca-125/sangre , Disgerminoma/tratamiento farmacológico , Disgerminoma/cirugía , Femenino , Humanos , L-Lactato Deshidrogenasa/sangre , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/cirugía , Ovario/patología , Salpingooforectomía/métodosRESUMEN
A 13-yr-old boy with recurrent acute myeloid leukemia underwent HSCT using cells from an unrelated donor who matched all HLA antigens except one. Forty-two days later, the patient developed a steroid-refractory hepatitic variant of liver GVHD with peak ALT and T.Bil values of 1406 mU/mL and 10.4 mg/dL, respectively. He was successfully treated with pulse Cy (1000 mg/dose × one day) without a change in chimerism being observed or acquiring an infection. All immunosuppressant therapies could be discontinued 12 months after HSCT. Two yr after HSCT, the patient remains in CR without chronic GVHD. This single case report suggests that pulse Cy may be a promising therapy for steroid-refractory GVHD, especially hepatitic GVHD, but needs to be further tested in clinical trials.
Asunto(s)
Ciclofosfamida/administración & dosificación , Enfermedad Injerto contra Huésped/terapia , Hepatitis/tratamiento farmacológico , Fallo Hepático/terapia , Fallo Hepático/virología , Esteroides/efectos adversos , Adolescente , Resistencia a Medicamentos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Inmunosupresores/uso terapéutico , Leucemia Mieloide Aguda/complicaciones , Leucemia Mieloide Aguda/terapia , Masculino , Factores de Tiempo , Acondicionamiento Pretrasplante/efectos adversos , Trasplante Homólogo , Resultado del TratamientoRESUMEN
A 10-year-old Japanese boy developed acute hepatitis with high levels of serum Torque teno virus DNA and marked lymphocytopenia, especially CD4 T-lymphocytopenia. Although the total lymphocyte counts rose as the patient recovered from hepatitis, this was largely because of a marked rise in CD8 cells. In contrast, CD4 cells recovered poorly, resulting in a further striking fall in the CD4/8 ratio. Two months later, the patient developed hepatitis-associated aplastic anemia. He was successfully treated with immunosuppressive therapy, which normalized the lymphocyte subset proportions. T-cell subsets analysis at the onset of hepatitis might be useful for predicting development of hepatitis-associated aplastic anemia.
Asunto(s)
Anemia Aplásica/etiología , Linfocitos T CD4-Positivos/inmunología , Hepatitis Viral Humana/complicaciones , Linfopenia/etiología , Torque teno virus/aislamiento & purificación , Enfermedad Aguda , Niño , Hepatitis Viral Humana/inmunología , Humanos , MasculinoRESUMEN
CONTEXT: Few instruments in Japanese assess health-related quality of life in pediatric cancer patients. OBJECTIVES: To translate the Memorial Symptom Assessment Scale (MSAS) into Japanese pediatric and proxy versions (MSAS-J 7-12, MSAS-J 13-18, and MSAS-J-Proxy) and assess validity and reliability. METHODS: Phase I comprised forward-backward translation and pilot testing in 13 children and 16 guardians. Phase II consisted of psychometric testing of the three MSAS-J versions in 162 children and 238 guardians. Internal consistency, test-retest reliability, and construct and known-group validity of the MSAS-J were assessed. RESULTS: Cronbach's alpha coefficients for the total and subscale scores were over 0.70, excluding the psychological symptom (PSYCH) subscale score of the MSAS-J 7-12. Most MSAS-J scores significantly inversely correlated with two versions of the Pediatric Quality of Life Inventory. A strong child-guardian correlation was shown in the total and subscale scores (ICC range 0.66-0.83). Kappa estimates showed acceptable child-guardian symptom agreement. MSAS-J 7-12 and proxy differentiated patients according to clinical status. CONCLUSION: MSAS-J is a reliable and valid instrument to assess symptoms among Japanese children with cancer.
Asunto(s)
Neoplasias , Calidad de Vida , Niño , Humanos , Japón , Neoplasias/diagnóstico , Neoplasias/psicología , Psicometría , Reproducibilidad de los Resultados , Encuestas y Cuestionarios , Evaluación de SíntomasRESUMEN
In Langerhans cell histiocytosis (LCH), somatic gene mutations in the mitogen-activated protein kinase pathway have been identified in more than 80% of cases in Western countries, in which mutually exclusive BRAF and MAP2K1 mutations are involved. Among them, BRAF V600E mutation is the major contributor (50-60%). In 59 patients (50 children and nine adults) with LCH (not including pulmonary LCH) in Japan, we first screened for BRAF V600E in all patients followed by target sequencing for other gene mutations in 17 of BRAF V600E-negative patients. As a result, BRAF V600E mutation was detected in 27/59 (46%) patients. We also identified BRAF mutations other than V600E in five and MAP2K1 mutations in nine patients. Thus, gene mutations in BRAF or MAP2K1 were identified in 41/44 (93%) of the fully tested patients. Regarding the correlation of clinical features and genotype in pediatric patients, we found that BRAF V600E mutation status was not correlated with sex, age at diagnosis, disease extent, response to first-line therapy, relapse, or CNS-related sequelae. Interestingly, MAP2K1 exon 2 in-frame deletion was related to the risk organ involvement; however, further studies are required to clarify the impact of these gene mutations on the clinical features of patients with LCH.
Asunto(s)
Estudios de Asociación Genética , Histiocitosis de Células de Langerhans/genética , MAP Quinasa Quinasa 1/genética , Mutación , Proteínas Proto-Oncogénicas B-raf/genética , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Japón , Sistema de Señalización de MAP Quinasas/genética , MasculinoRESUMEN
Patients with hemophilia and high titers of inhibitors are hard to treat during bleeding events and consequently are more likely to incur high treatment costs and to experience deterioration in quality of life. We report here the case of a boy with hemophilia A and high titers of inhibitors who responded well to prophylactic activated prothrombin complex concentrate (APCC) treatment. Previously, he had to be hospitalized frequently because of painful bleeding of target joints of the knee and ankle. At the age of 4 years and 3 months, APCC prophylaxis at a dose of 60 U/kg, three times a week, was initiated together with on-demand therapy with recombinant factor VIIa. This reduced the frequency and severity of bleeding and ended the need for hospitalization. This, together with a decreased requirement for bypass agents, APCC treatment significantly reduced the cost of treatment for this patient.
Asunto(s)
Factores de Coagulación Sanguínea/economía , Factor VIIa/economía , Hemofilia A/economía , Hemorragia/economía , Inhibidores de Factor de Coagulación Sanguínea/análisis , Factores de Coagulación Sanguínea/administración & dosificación , Factores de Coagulación Sanguínea/uso terapéutico , Preescolar , Análisis Costo-Beneficio , Factor VIIa/administración & dosificación , Factor VIIa/uso terapéutico , Hemofilia A/sangre , Hemofilia A/complicaciones , Hemofilia A/tratamiento farmacológico , Hemorragia/sangre , Hemorragia/complicaciones , Hemorragia/tratamiento farmacológico , Hospitalización , Humanos , Articulaciones/efectos de los fármacos , Masculino , Protrombina/análisis , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/economía , Proteínas Recombinantes/uso terapéuticoRESUMEN
We report the case of a girl with Tay-Sachs disease who had convulsions and deteriorated rapidly after an upper respiratory infection at the age of 11 months. At the age of 16 months, her seizures became intractable and magnetic resonance imaging of the brain showed high signal intensity on T2-weighted images and marked swelling in the white matter and basal nucelei of the right hemisphere. Her seizures and right hemisphere lesion improved with glycerol and dexamethasone treatment. When dexamethasone was discontinued, her symptoms worsened and lesions later appeared in the left hemisphere. Her cerebrospinal fluid showed elevated levels of the cytokines TNF-alpha and IL-5. It is considered that inflammation contributes to disease progression in Tay-Sachs disease.